The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated a Phase III trial of a dengue fever vaccine. The trial to evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, has begun at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) Rohtak, media reports said.
Union health minister JP Nadda said, “The initiation of this phase III clinical trial for India’s first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India’s capabilities in vaccine research and development.
“Through this collaboration between ICMR and Panacea Biotec, we are not only taking a step towards ensuring the health and well-being of our people but also reinforcing our vision of Atmanirbhar Bharat in the healthcare sector.”
The Phase 3 clinical trial, conducted in collaboration with ICMR, will take place across 19 sites in 18 states and Union territories, involving over 10,335 healthy adult participants.
DengiAll is based on the tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH), which has shown promise in previous studies.
